Nuvisan, based in Waltrop, Germany, will use ERS'w Genomics CRISPR-Cas9 portfolio to help advance its clients' drug discovery and early development programs.
The company showed that its chip can detect SNPs in models of sickle-cell disease and amyotrophic lateral sclerosis, without the need for DNA amplification.
The genome engineering company has started shipping its Onyx platform commercially, including to the University of Liverpool's synthetic biology foundry GeneMill.
This webinar, the first in a “Meet the Authors” series sponsored by Mission Bio, will discuss the application of single-cell analysis to decipher clonal evolution across several stages of disease development in myeloid malignancies.
